BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Bought by Curi RMB Capital LLC

Curi RMB Capital LLC increased its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 0.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 421,933 shares of the medical equipment provider’s stock after buying an additional 2,283 shares during the quarter. Curi RMB Capital LLC’s holdings in BioLife Solutions were worth $10,565,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Summit Global Investments purchased a new stake in BioLife Solutions during the 3rd quarter worth $228,000. Principal Financial Group Inc. grew its stake in shares of BioLife Solutions by 4.7% during the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock valued at $4,776,000 after acquiring an additional 8,580 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in shares of BioLife Solutions by 31.0% during the third quarter. Harbor Capital Advisors Inc. now owns 52,449 shares of the medical equipment provider’s stock worth $1,313,000 after acquiring an additional 12,421 shares during the last quarter. Raymond James & Associates lifted its stake in shares of BioLife Solutions by 4.3% in the third quarter. Raymond James & Associates now owns 139,997 shares of the medical equipment provider’s stock worth $3,506,000 after acquiring an additional 5,803 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BLFS has been the topic of a number of recent analyst reports. TD Cowen upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday. Northland Securities upped their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. HC Wainwright started coverage on BioLife Solutions in a report on Monday, September 30th. They issued a “buy” rating and a $29.00 price objective for the company. Finally, Craig Hallum lifted their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.83.

BioLife Solutions Stock Down 10.2 %

Shares of BioLife Solutions stock opened at $21.65 on Friday. The stock has a market capitalization of $998.93 million, a price-to-earnings ratio of -20.42 and a beta of 1.88. BioLife Solutions, Inc. has a twelve month low of $11.40 and a twelve month high of $28.88. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. The business’s 50 day simple moving average is $24.05 and its 200-day simple moving average is $22.72.

Insider Buying and Selling

In related news, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total value of $239,000.00. Following the completion of the transaction, the executive vice president now directly owns 317,716 shares of the company’s stock, valued at $7,593,412.40. This represents a 3.05 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the sale, the executive now directly owns 114,773 shares in the company, valued at $2,883,097.76. The trade was a 2.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,471 shares of company stock worth $656,330 in the last three months. 2.20% of the stock is owned by insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.